Literature DB >> 17211351

Lung cancer after treatment for non-Hodgkin lymphoma.

T De Giacomo1, M Martelli, F Venuta, M Anile, D Diso, M Di Stasio, E A Rendina, G F Coloni.   

Abstract

AIM: Because of the improvement in treatment and survival of patients with lymphoma, late sequelae, including secondary cancers have been extensively studied. Lung cancer is one of the two most common solid tumors after Hodgkin's disease but fewer studies have been published about lung cancer after non-Hodgkin lymphoma (NHL).
METHODS: Over the last five years at our Institution we have observed 16 patients, 13 male and 3 female, with a mean age of 61 years, previously treated for NHL and lung cancer. Median latency between NHL and lung cancer was 7 years. In 6 patients (37.5%) the latency period was shorter than 5 years and 3 of them developed lung cancer within 2 years after the end of NHL therapy.
RESULTS: Ten patients underwent lung complete resection. Two, 3 and 5 year survival rate was respectively 52.7%, 26.3% and 13%. In contrast, the median survival of non surgical patients was 9 months. Comparison of survival between surgical and non-surgical group demonstrated a statistically significant better survival for surgically treated patients (P<0.04).
CONCLUSIONS: Surgery can improve survival in patients with history of NHL and lung cancer. Early diagnosis and treatment is crucial. NHL survivors should undergo careful follow-up and surveillance for secondary malignancy.

Entities:  

Mesh:

Year:  2006        PMID: 17211351

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  2 in total

1.  Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients.

Authors:  Michael T Milano; Huilin Li; Louis S Constine; Lois B Travis
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

2.  Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study).

Authors:  Alfonso Fiorelli; Antonio D'Andrilli; Annalisa Carlucci; Giovanni Vicidomini; Domenico Loizzi; Nicoletta Pia Ardò; Rita Daniela Marasco; Luigi Ventura; Luca Ampollini; Paolo Carbognani; Giovanni Bocchialini; Filippo Lococo; Massimiliano Paci; Teresa Severina Di Stefano; Francesco Ardissone; Matteo Gagliasso; Paolo Mendogni; Lorenzo Rosso; Alessandra Mazzucco; Camilla Vanni; Beatrice Trabalza Marinucci; Rossella Potenza; Alberto Matricardi; Mark Ragusa; Valentina Tassi; Marco Anile; Camilla Poggi; Nicola Serra; Antonello Sica; Mario Nosotti; Francesco Sollitto; Federico Venuta; Erino Angelo Rendina; Francesco Puma; Mario Santini
Journal:  Transl Lung Cancer Res       Date:  2020-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.